Abstract
BackgroundTocilizumab (TCZ), a humanized anti-IL-6 receptor (IL-6R) monoclonal antibody, specifically inhibits IL-6 activity by competitively binding to soluble (sIL-6R) and membrane-bound IL-6R. As for infliximab, a chimeric anti-TNF-α monoclonal antibody,...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
